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Abstract 
Allocating resources for the prevention of HIV infection among injecting drug users 
(IDUs) in transitional and developing countries can be a challenging task.  The resources 
available are likely to be quite limited.  But pilot programs are unlikely to have any 
meaningful effect on the transmission of HIV in IDU populations.  There is also reason to 
believe that if prevention programming can reach a critical level in a local IDU 
population that very strong prevention effects can be achieved.  The resource allocation 
question can be phrased in terms of 1) what interventions should be implemented? And 2) 
what level of “coverage” of the interventions should be achieved?  We conducted a 
survey of 19 experts in HIV prevention to address these questions.  There was strong 
agreement regarding which interventions are “very important,” with almost all 
respondents mentioning needle/syringe programs, outreach programs and drug abuse 
treatment (particularly opiate substitution treatment).  There was modest agreement with 
respect to coverage, with a majority of the respondents giving a coverage of 20% to 33% 
of injections with new equipment obtained from needle/syringe programs and capacity to 
provide treatment for 20% to 33% of the local IDU population. Given cost factors, 
needle/syringe programs and outreach might be prioritized first in conditions of limited 
resources. While noting the need for local information and the multiple purposes of 
different programs, and the possibility that HIV prevalence and incidence rates might 
require higher coverage rates, we suggest that the agreement among these experts can be 
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 used for the initial planning of prevention programs for IDUs in transitional and 
developing countries.  An agenda for future research on coverage is presented.   
 3
 Introduction 
Rates of transmission of HIV among injecting drug users (IDUs) present some 
extreme contrasts.  Multi-person use (“sharing”) of needles and syringes is a relatively 
efficient means of transmitting HIV and there are many examples of extremely rapid 
spread of HIV within populations of injecting drug users.  HIV incidence rates of 10/100 
person-years to 50/100 person-years have been reported (UNAIDS, 2006).  
IDUs are also quite capable of reducing their injection risk behaviors (Des Jarlais 
et al., 2000b; Friedman et al., 1987; Friedman, Curtis, Neaigus, Jose, & Des Jarlais, 
1999) and there have been outstanding examples of HIV prevention programming for 
IDUs.  In many areas in industrialized countries, it has been possible to keep prevalence 
low indefinitely, literally preventing HIV epidemics among IDUs (Des Jarlais et al., 
1998; Stimson, 1995; Wodak, 1998).  It is also possible to “reverse” large-scale HIV 
epidemics among IDUs (greatly reduce both HIV incidence and prevalence) with large 
scale prevention efforts applied over long time periods.(Des Jarlais et al., 2005; 
Emmanuelli & Desenclos, 2005; Santibanez et al., 2006) 
The problem.  There are three interrelated technical problems with implementing HIV 
prevention programs for IDUs in developing and transitional countries.  First, the 
resources available for HIV prevention among IDUs are likely to be quite limited.  
Second, it is important to begin HIV prevention for IDUs early.  Delay in implementing 
programs permits the virus to spread within the IDU population, making it more difficult 
to prevent both further transmission among IDUs and transmission from IDUs to non-
drug injecting sexual partners.  Thus, it may be necessary to plan and implement 
prevention programs without having all of the information one would like to have.  Third, 
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 pilot programs do not stop epidemics.  If HIV prevention for IDUs is to be effective at the 
community level, it will be necessary to implement programs on a public health scale 
rather than a pilot program scale.   
The idea of implementing prevention on a public health scale is particularly 
important with respect to “critical level” prevention effects.  It is not necessary to 
eliminate risk behavior in a population of IDUs in order to dramatically reduce HIV 
transmission.  It is very likely that there is a critical level of risk reduction at which actual 
cases of HIV transmission become relatively uncommon events despite some continuing 
risk behaviors.  The critical levels would represent non-linearities in the relationship 
between risk behavior and HIV incidence, where small additional reductions in risk 
behavior would result in large reductions in HIV incidence.  That HIV prevalence has 
often stabilized shortly after large-scale risk reduction in low (Des Jarlais et al., 1995; 
Kemp & MacDonald, 1999; Stimson, 1995; Wodak, 1995) and high (Des Jarlais et al., 
1992; Kaldor, Elford, Wodak, Crofts, & Kidd, 1993) seroprevalence areas strongly 
suggests that critical level prevention effects occur. When implementing HIV prevention 
at a public health scale, one would want to implement at the scale needed to obtain such 
critical level effects.   
The need for expert judgment.  The three issues of limited resources, the need for early 
implementation, and the need for sufficiently large programs can make planning and 
budgeting for HIV prevention a complex and difficult task.  Empirical research should be 
able to provide an evidence base to guide such planning and budgeting.  This is not the 
type of research question, however, that can be readily addressed through standard 
methods such as randomized clinical trials.  Randomization at a community level would 
 5
 be logistically difficult, resource intensive, and unethical in many situations.  
Additionally, there are a potentially large number of variables in community-level HIV 
prevention, including different types of programs and different levels of implementation 
and different combinations of programs and levels of implementation.  Thus, the “gold 
standard” randomized clinical trial design is not likely to be usable for obtaining the 
needed information.   
Rather, the best methods may be expert analyses of case histories of the spread of 
HIV among IDUs in areas where there are good data on risk behavior, the social 
conditions of IDUs, prevention programming, and HIV transmission over time.  
Quantification and extension of the analyses through mathematical modeling might also 
be very useful, though expertise would clearly be required in deciding the assumptions, 
parameters and form of the models (Friedman et al., 2000; Grassly et al., 2003; 
Vickerman & Watts, 2002; Vickerman, 2001; Vickerman, Hickman, Rhodes, & Watts, 
2006).   
At present, there are no officially accepted guidelines for allocating resources to 
prevent HIV infection among IDUs, but decisions on allocation of resources still need to 
be made.  We conducted the present study in order to assess possible agreement and 
disagreement among experts regarding the types of programs considered important for 
preventing HIV infection among IDUs and the desirable level of implementation 
(coverage in the local IDU population).    
Methods 
We used a modification of the Delphi technique (Dalkey, 1969; Helmer-
Hirschberg, 1967; Linstone & Turoff, 1975).  In the Delphi technique, one first surveys a 
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 group of experts, using structured questions.  Next the responses are collated.  The 
answers are then fed back to the experts who are again asked the questions.  It is expected 
that some of the experts will modify their opinions based on the information provided by 
the others.  This process of survey, feedback and survey again is repeated until either a 
consensus emerges or a pattern of stable differences emerges.   
 Developing a limited set of questions to address the complexities of the types of 
prevention programs for IDUs and the coverage needed was challenging.  We first tried a 
moderately long series of fairly complex questions in an email questionnaire.  This 
questionnaire did produce some very useful responses, but it also was rather difficult for 
many of the respondents.  We then reduced the number of questions and used either face-
to-face or telephone interviews.  The great majority of the interviews were conducted 
face-to-face at various international meetings attended by the authors.  The sample of 
experts can thus be considered a convenience sample. The final questions were: 
1. What types of interventions do you believe are very important for preventing HIV 
transmission among IDUs? 
2. What level of “coverage” for each type of intervention do you believe is need to 
either prevent or stabilize an HIV epidemic among IDUs? 
3. Do you believe that the needed coverage will vary across low versus high HIV 
seroprevalence situations?   
The direct interaction format provided for immediate clarifications and the reduced 
number of questions led to most interviews taking about 15 minutes.  We then drafted a 
first version of the paper with the results of the first series of interviews and sent it to 
experts (including some who had not been previously interviewed) for comments.  In the 
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 comments on the first survey results, none of the experts indicated that they would 
change their estimates based on the estimates of the other experts.  This is not too 
surprising in that there was essentially consensus on which types of programs are “very 
important,” and that the idea of needed “coverage” has been frequently discussed in the 
field, without reaching consensus.  We did obtain estimates from seven additional experts 
in this second round of the survey, and their estimates are included in the results below.   
Results 
Results from the two rounds of interviews (n = 19) 
I.  Types of interventions needed: 
There was very strong agreement among respondents that the following types of 
interventions are “very important:” 
1. Needle-syringe programs, including exchange and/or distribution (all respondents 
agreed).   
2.  Community outreach, through outreach workers, peer educators, user groups, and 
from syringe exchange programs (all respondents agreed). 
3. Methadone maintenance or other substitution treatment in areas where opiates are the 
primary drugs used (all but one respondent agreed).  
II Coverage 
1.  Don’t know.  Four respondents replied, “Don’t know” for coverage in general and 
suggested conducting additional research and/or looking at existing modeling efforts.  
Another respondent provided coverage estimates for syringe exchange and substitution 
treatment but replied, “Don’t know” to outreach coverage. 
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 2.  Coverage for needle-syringe programs: 15 respondents gave estimates of 15% to 
60% of injections with new syringes obtained from syringe exchange programs.  There 
was a clear indication of a central tendency, with 11 suggesting coverage in the range 
of 20% to 33%.   
 3.  Coverage for outreach:  7 respondents gave estimates from 20% to 50% of the local 
IDU population reached on a regular basis (once per month or more frequently); 4 
suggested the need to reach close to 100% but did not discuss the regularity with which 
outreach needs to occur; 1 recommended reaching 30-50% within 2 years, and 
mentioned that targeted outreach is also needed for 20% to 30% of novice injectors; 
with another mentioning “user groups” without giving an estimate for coverage.  Two 
respondents recommended that targeted outreach be used to reduce injection frequency, 
but did not specify coverage levels.  There clearly was not any central tendency in the 
responses.   
 4.  Coverage for opiate substitution (methadone) treatment:  13 respondents gave 
estimates that sufficient treatment capacity is needed for 20% to 50% of the IDU 
population to be in substitution treatment.  There was a central tendency, with 11 
recommending coverage of 20% to 33%. 
 5.  Variation in coverage by epidemic situation: 13 respondents suggested that less 
coverage would be needed in low HIV prevalence situations compared to high-
prevalence situations, with 2 respondents suggesting that interventions with the same 
coverage would be needed for longer periods, and 1 respondent recommending no 
difference between low- and high-prevalence situations.  Of the 5 respondents who 
gave separate estimates, 2 suggested that coverage for syringe exchange would 
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 probably need to be approximately double in high prevalence situations compared to 
low prevalence situations, and 3 suggested that coverage of syringe exchange should be 
one-third to one-half higher in high-prevalence situations.   
6. In addition to the above three interventions, several other activities were mentioned 
by some respondents.  Interventions related to sexual transmission of HIV were 
recommended by 4 respondents, with coverage estimates provided by 2 respondents.  
One recommended of 100% (for both low- and high-prevalence situations), and the 
other recommended 60% to 80% in low-prevalence and over 80% in high-prevalence 
situations.  Policy and legal work (including addressing drug policies and laws that lead 
to high rates of incarceration of drug users), advocacy and a range of social service 
issues (assistance with employment, housing, family issues, etc.) were suggested by 3 
respondents.  A wide range of drug treatment options (in addition to substitution 
treatment) was recommended by 3 respondents, with one noting that there should be 
sufficient treatment to meet demand and that it should be easy to access.  One 
respondent each suggested the following interventions: Interventions in prisons with 
coverage of 100% of prisoners, treatment for HIV infection, voluntary counseling and 
testing, and safe injection facilities.   
As noted in the methods section above, when we circulated the results of the first 
survey round, we also asked for comments that the experts might have on the data.  The 
two most frequent comments were that the survey had addressed the major issues in the 
area, and that “more research is needed.”   
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 Discussion 
Limitations of the Delphi technique.   Several limitations of the Delphi technique should 
be noted.  First, the technique is designed to capture common ground in the opinions of 
experts in a given field.  It is not designed to generate new provocative new ideas, as a 
brain storming session might.  A second limitation of the Delphi technique is that there is 
no external validation of the opinions of the experts.  Thus, it may be that even where 
there is consensus among the experts, the consensus opinion of experts might be 
“wrong.”   
The Delphi technique also requires simplification of the questions to be 
addressed.  Two simplifying assumptions should be noted here.  The first simplifying 
assumption is that the social and legal environments are supportive of (or at least not 
opposed to) HIV prevention programs for injecting drug users.  Planning the scale of the 
prevention programs is likely to be irrelevant if the social and legal environment does not 
permit the drug users to utilize the programs.  A second simplification is that the 
programs are only in terms of preventing HIV infections.  HIV prevention programs may 
provide a large number of services to drug users, including preventing hepatitis B and 
hepatitis C infection, and linking drug users to other social and health services, and 
preventing transmission of HIV from IDUs to non-injecting sexual partners.  These other 
functions certainly may support HIV prevention among IDUs, but they also can clearly 
go beyond HIV prevention among IDUs.  Including these other goals would greatly 
complicate any attempt to estimate the needed levels of program implementation.   
General Level of Agreement.  Given the absence of anything close to definitive data on 
stabilizing HIV prevalence in populations of IDUs, there was very strong agreement on 
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 the “very important” types of interventions” and moderate agreement on the desired 
coverage levels for needle/syringe programs and for opiate pharmacotherapy treatment.  
Some of this agreement undoubtedly reflects discussion of the interventions and coverage 
estimates among experts in the field, including those who were interviewed.  We do 
believe that the areas of agreement in the results can be used as general guidelines for 
planning HIV prevention programs for IDU populations, while cautioning that a 
meaningful proportion of experts thought higher needle/syringe coverage might be 
needed.   
 In the interviews, we did not attempt to code the rationales of each expert for why 
a particular intervention was “very important” or for the coverage level for each specified 
intervention.  While it would be very interesting to examine the different rationales, 
doing this would be a very labor-intensive exercise and was beyond the scope of this 
project.  A number of interpretative comments are provided below, particularly with 
respect to the coverage estimates.   
Why “very important?”  Three interventions—needle/syringe programs, outreach and 
substitution therapy (in areas where heroin is the primary drug used) were consistently 
mentioned as very important.  This is in agreement with the US National Institutes of 
Health Consensus Development Conference (NIH, 1997) and the WHO Evidence for 
Action reports (WHO, 2004) that these three interventions are effective in reducing 
injection risk behavior among IDUs.   
 Two of these—needle/syringe programs and community outreach—may be not 
only “very important” but “necessary” for stabilizing HIV prevalence in populations of 
IDUs.  It is difficult to imagine how IDUs could practice large-scale safer injection 
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 without access to sterile needles and syringes.  Similarly, it is difficult to imagine how 
IDUs would come to practice large-scale safer injection without accurate information on 
HIV/AIDS, how it is transmitted, and how risks can be reduced.  In some situations, such 
information may diffuse through media coverage of HIV/AIDS and diffusion efforts of 
IDUs themselves.  However, it clearly would be important for public health authorities to 
initiate diffusion of accurate information on HIV/AIDS rather than wait to see if formal 
programs were not needed.  Additionally, community outreach serves to help change the 
social norms in the IDU population to proscribe the sharing of injection risk behavior and 
to socially reinforce risk reduction.  Again, it is difficult to envision how large-scale risk 
reduction could become self-sustaining without the appropriate changes in IDU 
community norms.  Thus, in many communities, both needle/syringe programs and some 
form of outreach programming may be necessary to stabilize HIV prevalence in 
populations of IDUs.  It is also relatively easy to envision how needle/syringe programs 
and community outreach programs might generate critical level prevention effects.   
 One additional aspect of community outreach should be noted.  It may be possible 
to conduct outreach efforts in combination with other prevention activities, such as 
syringe exchange.  Indeed, successful syringe exchange may require some degree of 
outreach in order to inform users of the exchange services.  Exchange sites may also 
serve as sources of information about HIV/AIDS that then diffuses through the local IDU 
population.   
 Providing effective drug abuse treatment (substitution therapy in particular) may 
have a qualitatively different type of importance.  Drug abuse treatment can certainly 
reduce injecting and thus reduce the chances that individuals would become infected with 
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 HIV and transmit HIV to others. (Friedman, Jose, Deren, Des Jarlais, & Neaigus, 1995; 
Metzger & Navaline, 2003)  The potential for generating critical level effects from 
providing drug abuse treatment would seem to be more limited.  Simply taking a random 
sample of drug injectors into treatment would serve to reduce the size of the IDU 
population at risk, but would not affect transmission among those who are not in 
treatment.  If the treatment were targeted to persons who were particularly likely to 
become infected and/or to transmit to others, then potential critical level prevention 
effects might be possible.  If, in a low prevalence community, a large percentage of the 
HIV seropositive IDUs entered drug abuse treatment, this could reduce transmission the 
population as a whole.   
 Drug abuse treatment can be important for preventing HIV infection in several 
other ways.  Being on methadone or other substitution treatment may greatly increase the 
ability of former IDUs to work as peer educators and or as staff of syringe exchanges or 
as staff of users’ group. (Des Jarlais, et al., 2004a; Friedman, de Jong, & Des Jarlais, 
1988)  Additionally, providing effective drug abuse treatment may also help assure drug 
users, political leaders, law enforcement officials, and the community as a whole that the 
HIV prevention efforts include addressing the many potential harms associated with 
injecting illicit drugs and not just HIV infection.  This can increase acceptance of the 
prevention programs in both the IDU population and the community as a whole.   
Coverage Estimates. 
Needle/syringe programs.  The majority of the coverage estimates were that 20% to 33% 
of injections should be made with a needle and syringe obtained from a program source 
(and thus guaranteed to be free of HIV), although there was considerable overall range in 
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 these estimates, with some experts saying more coverage is needed, and a common belief 
that a high local HIV seroprevalence level might require higher levels of coverage.  
These estimates are substantially lower than the 60% estimate that has been often been 
discussed previously.  These lower estimates may reflect greater appreciation of several 
factors, including: 1) drug users may re-use their own needles and syringes multiple times 
without risk of HIV infection, and 2) drug users may share needles and syringes within 
small, stable groups with only very modest risk of HIV transmission.(Des Jarlais, et al., 
2004b).  The difference may also reflect a clarification in coverage.  We used the 
percentage of injections with syringes obtained from a needle/syringe program, while 
previous estimates of coverage may have focused on the percentage of IDUs who were 
regularly using needle/syringe programs.   
Outreach programs.  A number of the respondents preferred to use their own definitions 
of coverage so that comparing the estimates for coverage is difficult.  Other respondents 
specified mechanisms for providing outreach (build from syringe exchanges, users’ 
groups) without giving numerical estimates.  Thus, unlike the coverage estimates for 
needle/syringe programs, there was no clear central tendency.  The difficulties in making 
coverage estimates for outreach may reflect a lack of quantitative research on the 
diffusion of HIV-related information among IDU populations and how such information 
may lead to the development and maintenance of social norms promoting risk reduction.   
Drug abuse treatment (substitution treatment) programs in areas where opiates are the 
primary drug being injected.  A majority of the respondents gave coverage estimates that 
would provide treatment for from 20% to 33% of the local IDU population at any point in 
time.   This is a relatively high level, perhaps currently attained in some, but certainly not 
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 all, industrialized countries and in few, if any, developing/transitional countries (Ball, 
Rana, & Dehne, 1998; Stimson, Adelekan, & Rhodes, 1996).  For example, in a study of 
US metropolitan areas, the median metropolitan area provided treatment to only 8.6% of 
its IDUs (Friedman et al., 2004a).  As noted above providing drug abuse treatment may 
be very important for many reasons beyond a simple reduction in HIV risk behavior and 
HIV transmission.   
 “It depends,” and modeling.  Several of the respondents did not give coverage estimates 
for the three interventions, but specifically noted that the desired coverage levels would 
depend greatly on local conditions, and referred to mathematical modeling (Friedman et 
al., 2000; Grassly et al., 2003; Vickerman & Watts, 2002; Vickerman, 2001; Vickerman 
et al., 2006); as a method for setting coverage targets within the local conditions.  Local 
conditions could include the types of drugs injected and changes in the types of drugs 
injected, locations in which drugs are used, tendencies for IDUs to re-use their own 
injection equipment, patterns of law enforcement, different patterns of social networks, 
and residential conditions (homelessness) within the IDU community. Additionally, 
many of the respondents indicated that higher coverage levels would be required in high 
HIV seroprevalence populations. The currently existing HIV seroprevalence and HIV 
incidence may be considered as primary local conditions for both HIV prevention 
planning and for modeling efforts.   
 In addition to historical epidemiological studies, much could be learned from 
mathematical modeling of HIV transmission among IDUs.  Modeling would need to 
incorporate the important initial local conditions and the effects of interventions on risk 
behaviors to generate the resulting patterns of HIV transmission over time.  Fully 
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 developed models could contribute considerably to estimating the coverage needed to 
control HIV transmission in populations of IDUs.  In our assessment, important advances 
have been made in modeling the effects of needle/syringe programs on the frequency of 
sharing (Kaplan & Heimer, 1992; Kretschmar & Wiessing, 1998; Vickerman et al., 
2006).  However, we do not have working models for how various interventions might 
affect network parameters such as rates of partner change (how many different people an 
injector shares with per unit of time) and the size and interconnectedness of groups within 
which syringes are shared.  Without a better understanding of how interventions affect 
network parameters, it is difficult to use modeling to estimate the coverage needed for 
different interventions to reduce HIV transmission among IDUs.  We also do not have 
models that incorporate fundamental changes in local drug scenes, such as large increases 
in cocaine or amphetamine injection, and how these might change the need for various 
interventions.   
Data for Planning and Evaluation.  While the respondents were willing to estimate 
coverage targets in general, they also recognized the need for considering local 
conditions in allocating resources for HIV prevention for IDUs.  It may be difficult to 
obtain sufficient local conditions information before prevention planning must be done.  
We would recommend, however, that at least a Rapid Assessment (Fitch, 2004; Stimson 
et al., 2006; WHO, 1998) and some HIV seroprevalence data be collected.   
 Once programs have been implemented it is critical to obtain ongoing process and 
outcome evaluation.  Outreach programs, including peer educators and through users’ 
groups, can be important sources of qualitative data.  (Some training in systematic data 
collection and interpretation would be required.)  Where feasible, professional 
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 ethnographic studies of the local drug scenes can also provide very valuable information.  
The numbers of syringes and condoms being distributed are very important quantitative 
indicators.  Periodic surveys of HIV seroprevalence (and ideally incidence) can serve as 
outcome measures.  Conducting cohort studies to estimate incidence is likely to be too 
resource intensive, but it may be possible to estimate incidence using serologic tests for 
recent infections or using prevalence among new injectors.   
Costs.  The costs per IDU served vary greatly across the three types of interventions, with 
drug abuse treatment likely to be by far the most expensive on a per person served basis.  
We would thus suggest that priority be given to reaching the desired coverage levels for 
needle/syringe and outreach programs before attempting to reach the desired coverage 
level for drug abuse treatment.   
Conclusions 
There is an urgent need to scale up HIV prevention programs for injecting drug 
users in many areas of the world.  Scaling up often requires obtaining new resources and 
the allocation of scarce resources.  It is important to allocate sufficient resources to obtain 
likely critical level effects in reducing HIV transmission and stabilizing HIV prevalence 
in populations of IDUs. 
 There currently are no randomized controlled trials nor yet any well-validated 
models for scaling up.  This survey of experts in the field did find strong agreement with 
respect to the types of prevention programs that are very important and a moderate 
agreement on the levels of coverage for needle/syringe programs and drug abuse 
treatment programs.  Needle/syringe programs, community outreach programs and drug 
abuse treatment (particularly narcotic substitution therapy) were all considered very 
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 important.  Needle/syringe programs and outreach may be necessary for stabilizing HIV 
prevalence among populations of IDUs, while drug abuse treatment programs may be 
important for a wider variety of reasons. 
 Coverage estimates were generally in the range of 20% to 33% for needle/syringe 
programs, (though there was some important variation, with some experts calling for 
much higher coverage).  This 20% to 33% is substantially lower than the 60% coverage 
previously considered for needle/syringe programs, and may reflect greater consideration 
of the “relative safety” of injectors re-using their own needles and syringes and of 
confining sharing within small stable groups.  We believe that both the types of 
interventions and the needle/syringe coverage estimates presented here can be used for 
planning HIV prevention efforts in many different areas.  We would, however, also 
emphasize the need for obtaining local information and for continuing evaluation of the 
prevention efforts.   
Research Agenda.  Finally, this survey of experts also points to the need for additional 
research on the question of coverage needed for different interventions. One particular 
topic for additional research is the coverage needed for outreach/community education 
interventions.  There was no central tendency in the estimates of the coverage needed for 
outreach programs and the estimates ranged widely.  We would like to propose a research 
agenda that would both formulate specific questions for outreach coverage and link 
outreach coverage to needle/syringe coverage.  Diffusion of innovations theory (Rogers, 
2003) and social network theory (Latkin, Hua, & Davey, 2004; Latkin & Knowlton, 
2005; Friedman et al., 1997; Friedman et al., 2000) would both predict that outreach 
workers should be able to deliver information about HIV/AIDS to enough injecting drug 
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 users that the information then spreads throughout the population of IDUs.  Diffusion of 
innovation theory suggests that it may be necessary to reach only a modest proportion of 
the IDU population, perhaps 10 to 20%, in order to set off the diffusion of information. 
Research of this type needs to consider the level and content of pre-existing HIV/health 
communication among drug users (and those around them), including the possibility that 
the users might already be disseminating information and suggestions as good as, or even 
better than, that provided by the outreach (Friedman et al., 2004b).   
 Widespread diffusion of accurate HIV/AIDS information within a population of 
IDUs should then lead to: 1) increased demand for clean injection equipment, 2) the 
development of new social norms against sharing needles and syringes in general, and 3) 
new social norms against sharing needles and syringes outside of small networks (sexual 
partners, close friends, relatives).  Based on our own studies of HIV prevention in 
industrialized countries (Des Jarlais et al., 1995; Des Jarlais et al., 2000a; Des Jarlais et 
al., 2000b; Des Jarlais et al., 1998; Des Jarlais et al., 2005), we would suggest that HIV 
epidemics among IDUs can be controlled when approximately 70% of IDUs report no 
sharing of needles and syringes, 95% report no sharing outside of small social networks, 
and coverage (in terms of having a clean needle and syringe for each injection is 
approximately 20%).   
There are, of course, potentially important barriers to this community level risk 
reduction process.  First, there may be important divisions among the IDUs that restrict 
the flow of information and the development of new social norms.  These may include 
racial/ethnic divisions, socio-economic divisions, gender, sexual orientation, and 
geographic separation.  There may also be important limitations on the ability of IDUs to 
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 obtain and use new needles and syringes, such as the lack of outlets, limits on the 
numbers of needles and syringes that can be obtained from outlets, and law enforcement 
activities that prevent/discourage drug users from obtaining, carrying and storing new 
needles and syringes.   
Conducting research on the process from outreach/information diffusion to 
increased demand for clean needles and syringes to the development of social norms 
against injection risk behavior to coverage of needle/syringe programs and control of 
HIV transmission would best be done through constructing good case histories of HIV 
prevention among IDUs in local communities.  As HIV prevention programs are 
implemented in new areas—hopefully on the scale needed to change IDU social norms 
and to provide needle/syringe coverage of 20% or more—there should be many 
opportunities to collect such case history data.  This would then be followed by 
mathematical modeling to examine common patterns across sites.  While additional 
empirical data and modeling would certainly be helpful, the task of estimating the needed 
“coverage” levels for different programs to prevent HIV transmission among IDUs is 
inherently complex and not amenable to reductionist research designs such as 
randomized clinical trials.  Thus, expert opinion will undoubtedly remain an important 
component of estimating coverage, and future surveys of agreement and disagreements 
among experts would also be useful.   
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